Allergy Therapeutics (LON:AGY) Stock Price Down 10.4% – Here’s Why

Allergy Therapeutics plc (LON:AGY) fell 10.4% during mid-day trading on Monday . The company traded as low as GBX 5.62 ($0.07) and last traded at GBX 6.28 ($0.08). 180,738 shares changed hands during trading, a decline of 66% from the average session volume of 535,030 shares. The stock had previously closed at GBX 7 ($0.09).

Allergy Therapeutics Stock Down 17.1 %

The firm has a market cap of £276.66 million, a P/E ratio of -96.67, a P/E/G ratio of -30.70 and a beta of 1.40. The firm’s fifty day moving average is GBX 6.53 and its 200 day moving average is GBX 5.42. The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings data on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 155.90% and a negative net margin of 94.29%. As a group, equities research analysts anticipate that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.